Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
This is an open label Phase II study to determine the rate of improvement in response of
patients with previously treated multiple myeloma to imetelstat alone or in combination with
lenalidomide maintenance therapy. This study will include multiple myeloma patients who
either have achieved disease stabilization or who have achieved at least a partial response
(PR) but failed to achieve a complete response (CR) after cytoreductive therapy for multiple
myeloma; ie, have detectable but non-progressing disease and will most likely relapse.